Navigating tarlatamab and bispecific T-cell engager therapy in small cell lung cancer: A narrative review
Cancer Treatment and Research Communications · 2026 · 49 · 101360
DOI: 10.1016/j.ctarc.2026.101360 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Berun A Abdalla. Beteiligte Einrichtung: Department of Scientific Affairs, Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Iraq; Kscien Organization for Scientific Research (Middl…. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Small cell lung cancer (SCLC) remains one of the most aggressive solid malignancies, characterized by early metastasis and a historically dismal prognosis once resistance to platinum-based chemotherapy develops. For decades, therapeutic progress has been stagnant, with outcomes in the relapsed setting showing limited improvement. The recent FDA approval of tarlatamab, a first-in-class Delta-like ligand 3 (DLL3)-targeting bispecific T-cell engager (BiTE), marks a pivotal evolution in thoracic oncology. Unlike traditional immune checkpoint inhibitors that rely on pre-existing immune recognition, tarlatamab actively redirects cytotoxic T-cells to lyse tumor cells, validating DLL3 as a therapeutic target following the failures of earlier antibody-drug conjugates. However, the integration of BiTE therapy into solid tumor practice introduces unique clinical challenges previously confined to hematologic malignancies. This review provides a comprehensive, practical roadmap for the solid tumor oncologist navigating this new therapeutic landscape. We offer a detailed examination of the safety profile, specifically focusing on the recognition, grading, and management of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Furthermore, we address the critical operational hurdles, including step-up dosing schedules and the logistical considerations for transitioning from inpatient monitoring to outpatient administration. Finally, the review analyzes emerging data on resistance mechanisms such as antigen downregulation and T-cell exhaustion to provide evidence-based guidance on patient selection and future treatment sequencing strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Scientific Affairs, Smart Health Tower, Madam Mitterrand Street, Sulaymaniyah, Iraq; Kscien Organization for Scientific Research (Middle East Office), Hamid Street, Sulaymaniyah, Iraq. Electronic address:…
Zitieren
APA
Abdalla, B. A. (2026). Navigating tarlatamab and bispecific T-cell engager therapy in small cell lung cancer: A narrative review. Cancer Treatment and Research Communications, 49, 101360. https://doi.org/10.1016/j.ctarc.2026.101360
Vancouver
Abdalla BA. Navigating tarlatamab and bispecific T-cell engager therapy in small cell lung cancer: A narrative review. Cancer Treatment and Research Communications. 2026;49:101360. doi:10.1016/j.ctarc.2026.101360
BibTeX
@article{Abdalla2026,
author = {Abdalla, Berun A},
title = {Navigating tarlatamab and bispecific T-cell engager therapy in small cell lung cancer: A narrative review},
journal = {Cancer Treatment and Research Communications},
year = {2026},
volume = {49},
pages = {101360},
doi = {10.1016/j.ctarc.2026.101360}
}
EUVIMED